CRISPR Therapeutics is still losing money, but it also finished March with $1.9 billion in cash after burning through $134 ...

In contrast, CRISPR’s product candidates are aimed at being a one-time and done treatment, tackling the root of the problem (see image below ... I/we have no stock, option or similar derivative ...

CRISPR Therapeutics' stock is down 19% since December, with a slow Casgevy launch and significant R&D investments, yet strong cash reserves provide a safety net. Q4 earnings show no revenue from ...

As its shareholders already know, CRISPR Therapeutics (NASDAQ ... and plenty of financial flexibility, there's no shortage of reasons to buy the stock. But even for those who appreciate the ...

Shares of CRISPR Therapeutics have lost 15.8% so far this year compared with the industry’s decline of 2.3%. Zacks Investment Research Image Source: Zacks Investment Research CRISPR Therapeutics ...